2 results
Approved WMOCompleted
To evaluate the effects of AMT-101 in combination with adalimumab on UC disease activity as measured by symptoms, endoscopy, histology, and biomarkers. To evaluate the safety and tolerability of oral AMT-101 over 8 weeksTo assess the PK parameters…
Approved WMORecruiting
We started to evaluated the feasibility of subcutaneous EEG electrodes in epilepsy patients undergoing VNS therapy in a pilot study. This part is currently finished.Currenrly, we are extending the cohort and aim to identify biomarkers to predict…